Active, not recruitingPhase 3NCT05696717
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Studying Multiple system atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Theravance Biopharma
- Intervention
- Ampreloxetine(drug)
- Enrollment
- 102 enrolled
- Eligibility
- 30 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
- The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
- UC San Diego Movement Disorder Center, La Jolla, California, United States
- David Geffen School of Medicine at UCLA, Los Angeles, California, United States
- Stanford Neuroscience Health Center, Palo Alto, California, United States
- Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Parkinson's Disease And Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
- SFM Clinical Research, LLC, Boca Raton, Florida, United States
- Aqualane Clinical Research, Naples, Florida, United States
- Neurostudies, Inc, Port Charlotte, Florida, United States
- University of South Florida Ataxia Research Center, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Hawaii Pacific Neuroscience, Honolulu, Hawaii, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Northshore University Health System, Glenview, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05696717 on ClinicalTrials.govOther trials for Multiple system atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07446894MSA-01 in Multiple System AtrophyTokyo University
- RECRUITINGPHASE2NCT07197866An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyTeva Branded Pharmaceutical Products R&D LLC
- ENROLLING BY INVITATIONNCT07081841AB-1005 Long-Term Follow-up StudyAskBio Inc
- RECRUITINGPHASE1, PHASE2NCT06831500Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.Julien Bally
- RECRUITINGEARLY PHASE1NCT06765733The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System AtrophyBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD
- RECRUITINGNCT07353463Shanghai Clinical Cohort - Parkinson's Disease (Reserve)Ruijin Hospital
- RECRUITINGEARLY PHASE1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA